Study: NCT02462473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.